Provided by Tiger Trade Technology Pte. Ltd.

Dare Bioscience

1.28
+0.02001.59%
Post-market: 1.26-0.0200-1.56%19:59 EDT
Volume:197.23K
Turnover:249.96K
Market Cap:19.17M
PE:-1.34
High:1.34
Open:1.28
Low:1.23
Close:1.26
52wk High:3.78
52wk Low:1.16
Shares:14.98M
Float Shares:13.73M
Volume Ratio:0.47
T/O Rate:1.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9564
EPS(LYR):-1.1986
ROE:-2543.13%
ROA:-32.21%
PB:26.13
PE(LYR):-1.07

Loading ...

Daré Bioscience, Inc. (NASDAQ:DARE): Are Analysts Optimistic?

Simply Wall St.
·
Jul 21

Daré Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth Opportunities

GlobeNewswire
·
Jul 20

Daré Bioscience Advances DARE-HPV Trial, Raising New Questions for HPV Treatment Investors

TIPRANKS
·
Jul 18

Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event

GlobeNewswire
·
Jul 09

Daré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer Platform

GlobeNewswire
·
Jul 01

Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” Segment

GlobeNewswire
·
Jun 25

Daré Bioscience CEO speaks at BIO International Convention 2026

Reuters
·
Jun 18

Daré Bioscience shareholders approve 1.5 million-share increase to 2022 stock incentive plan at annual meeting

Reuters
·
Jun 13

DarÉ Bioscience Announces the Upcoming Launch of Flora Sync Lf5™ Vaginal Probiotic Capsules

THOMSON REUTERS
·
Jun 04

Daré Bioscience wins $1 million NIH grant tranche for DARE-HPV program

Reuters
·
May 26

Press Release: Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

Dow Jones
·
May 26

BRIEF-Daré Bioscience Initiates Phase 2 Study Of Dare-Hpv

Reuters
·
May 18

Daré Bioscience starts Phase 2 trial of DARE-HPV vaginal insert for high-risk HPV infection

Reuters
·
May 18

DarÉ Bioscience Initiates Phase 2 Study of Dare-Hpv, a Novel Pharmacologic Treatment for Persistent High-Risk Hpv Infection With No FDA-Approved Therapies

THOMSON REUTERS
·
May 18

Dare Bioscience Inc - Dare-Hpv Development Supported by $10 Mln Arpa-H Contract; Topline Data Expected in 2027

THOMSON REUTERS
·
May 18

Dare Bioscience Inc - Phase 2 Study to Enroll About 100 Women Over up to 21 Days

THOMSON REUTERS
·
May 18

Dare Bioscience Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
May 15

BRIEF-Daré Bioscience Reports First Quarter 2026 Financial Results

Reuters
·
May 15

Dare Bioscience Q1 FY26 net loss narrows 31% to $3 million

Reuters
·
May 15

Dare Bioscience Q1 EPS $(0.20) Beats $(0.27) Estimate, Sales $152.455K Miss $984.667K Estimate

Benzinga
·
May 15